An Inducible Facioscapulohumeral muscular dystrophy (FSHD) Mouse Model Expressing DUX4
- Detailed Technology Description
- FSHD is the thirdmost common muscular dystrophy, affecting 1 in 20,000 individuals. There is nocurrent treatment for FSHD. Researchers at Nationwide Children's Hospital havedeveloped a mouse model that recapitulates FSHD phenotypes and developsmyopathy. This is the first FSHD mouse model that stably expresses the DUX4gene from the mouse genome using the human DUX4 promoter. This model alsocircumvents lethality, leakiness problems and transient expression inherent inthe standard mouse model.
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
FSHD is the thirdmost common muscular dystrophy, affecting 1 in 20,000 individuals. There is nocurrent treatment for FSHD. Researchers at Nationwide Children's Hospital havedeveloped a mouse model that recapitulates FSHD phenotypes and developsmyopathy. This is the first FSHD mouse model that stably expresses the DUX4gene from the mouse genome using the human DUX4 promoter. This model alsocircumvents lethality, leakiness problems and transient expression inherent inthe standard mouse model.
- *Inquiry
- Margaret Barkett, PhD The Research Institute at Nationwide Children's Hospital Office of Technology Commercialization 700 Children's Drive Columbus OH 43205 T: 614 355-2957 F: 614 722-2716 Margaret.barkett@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here
